Production (Stage)
LAVA Therapeutics N.V.
LVTX
$1.32
$0.021.54%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -28.04M | -25.17M | -27.59M | -24.14M | -28.54M |
| Total Depreciation and Amortization | 327.00K | 364.00K | 270.00K | 376.00K | 443.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -3.68M | 1.23M | 4.27M | 1.93M | 3.01M |
| Change in Net Operating Assets | 1.33M | 4.32M | -6.58M | -6.28M | -7.71M |
| Cash from Operations | -30.06M | -19.26M | -29.63M | -28.11M | -32.79M |
| Capital Expenditure | -23.00K | -46.00K | -47.00K | -30.00K | -254.00K |
| Sale of Property, Plant, and Equipment | -1.00K | 88.00K | 94.00K | 92.00K | 89.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 26.94M | 12.41M | -7.26M | -24.57M | -24.45M |
| Cash from Investing | 26.92M | 12.45M | -7.21M | -24.50M | -24.62M |
| Total Debt Issued | -130.00K | -130.00K | -130.00K | -106.00K | -117.00K |
| Total Debt Repaid | -458.00K | -458.00K | 484.00K | 348.00K | 214.00K |
| Issuance of Common Stock | 19.00K | 27.00K | 27.00K | 25.00K | 8.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -569.00K | -561.00K | 381.00K | 267.00K | 105.00K |
| Foreign Exchange rate Adjustments | 204.00K | -1.84M | 760.00K | -174.00K | -112.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.51M | -9.22M | -35.70M | -52.52M | -57.42M |